Refinements to the analytical testing of biosimilar candidates to verify similarity were worked into 2019 guidance from the FDA. These changes offer what the author considers a more "rational approach."
Analytical similarity assessment of biosimilar candidates is the backbone for establishing biosimilarity, a primary requirement for the licensing of biosimilars. After withdrawing its pivotal final guideline on analytical similarity testing, the FDA issued new guidance (Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations), with many apparent and subtle differences, primarily based on my citizen petition to the FDA. For example, few people noticed that the FDA replaced “testing” with “assessment.” To assess is to test the value of something using various tools. Testing is when something is put through a series of trials to determine its value. Thus, testing is one of the ways to assess something. In this paper, I will draw attention to both substantive and subtle changes to help reduce the cost and time for the approval of biosimilars.
We have come a long way from the early days of superfluous testing of biosimilars; the new FDA guidance should be read carefully between lines; it is a more rational approach to achieving the demonstration of biosimilarity, but the FDA is like any other agency—if you keep offering to assess ad infinitum, they will have no objection to it. Manufacturers must learn the difference between “testing” and “assessment.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.